Clinical Significance and Prognostic Value of Pentraxin-3 as Serologic Biomarker for Lung Cancer

Zhang, Dai; Ren, Wei-Hong; Gao, Yun; Wang, Nian-Yue; Wu, Wen-Jun

추천

검색

자료유형: 학술저널

저자정보: Zhang, Dai (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine) Ren, Wei-Hong (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine) Gao, Yun (Center of Clinical Laboratory, Henan Province Tumour Hospital) Wang, Nian-Yue (Department of Clinical Laboratory, the Second Affiliated Hospital of Southeast University) Wu, Wen-Jun (Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제7호

발행연도: 2013.1

수록면: 4,215 - 4,221 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purposes: Lung cancer is prevalent worldwide and improvements in timely and effective diagnosis are need. Pentraxin-3 as a novel serum marker for lung cancer (LC) has not been validated in large cohort studies. The aim of the study was to assess its clinical value in diagnosis and prognosis. Methods: We analyzed serum PTX-3 levels in a total of 1,605 patients with LC, benign lung diseases and healthy controls, as well as 493 non-lung cancer patients including 12 different types of cancers. Preoperative and postoperative data were further assessed in patients undergoing LC resection. The diagnostic performance of PTX-3 for LC and early-stage LC was assessed using receiver operating characteristics (ROC) by comparing with serum carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA 21-1). Results: Levels of PTX-3 in serum were significantly higher in patients with LC than all controls. ROC curves showed the optimum diagnostic cutoff was 8.03ng/mL (AUC 0.823, [95%CI 0.789-0.856], sensitivity 72.8%, and specificity 77.3% in the test cohort; 0.802, [95%CI 0.762-0.843], sensitivity 69.7%, and specificity 76.4% in the validate cohort). Similar diagnostic performance of PTX-3 was observed for early-stage LC. PTX-3 decreased following surgical resection of LC and increased with tumor recurrence. Significantly elevated PTX-3 levels were also seen in patients with non-lung cancers. Conclusions: The present data revealed that PTX-3 was significantly increased in both tissue and serum samples in LC patients. PTX-3 is a valuable biomarker for LC and improved identification of patients with LC and early-stage LC from those with non-malignant lung diseases.

#Lung neoplasm #serum marker #pentraxin-3 #diagnosis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Zhang, Dai

소속기관 Department of Clinical Laboratory, the First Affiliated Hospital of Henan University of Traditional